Hinge Health (NYSE:HNGE) Releases Quarterly Earnings Results, Beats Estimates By $0.31 EPS

Hinge Health (NYSE:HNGE) issued its earnings results on Tuesday. The company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.31, FiscalAI reports. Hinge Health had a negative net margin of 78.95% and a negative return on equity of 310.62%. The business had revenue of $212.82 million during the quarter. During the same quarter in the previous year, the company posted $0.59 EPS. The company’s quarterly revenue was up 53.0% on a year-over-year basis.

Here are the key takeaways from Hinge Health’s conference call:

• Q2 results exceeded expectations: Revenue grew 53% year over year to $213 million, operating margin expanded to 29%, and free cash flow rose to $100 million, or a 47% margin.
• Hinge Health raised its 2026 outlook to $856 million–$860 million of revenue and $236 million–$244 million of operating income, driven primarily by stronger-than-expected enrollment yields.
• The company’s platform expansion is gaining traction, with its migraine program reaching more than 450 clients and five million covered lives; it also agreed to acquire Cylinder Health for $105 million to enter gastrointestinal care.
• Commercial momentum remains strong, including an enterprise win covering nearly 300,000 lives, SMB lives growth of more than 100% in the first half, and an opt-out partnership expected to add clients beginning in 2027.
• Cylinder is currently operating at a loss and will require product integration and investment over the next nine to 24 months, potentially pressuring near-term margins even though management expects it to approach Hinge’s profitability profile within one to two years.

Hinge Health Price Performance

NYSE:HNGE traded up $2.25 during trading hours on Tuesday, reaching $79.90. 2,526,861 shares of the company were exchanged, compared to its average volume of 1,504,626. The firm has a market cap of $6.18 billion, a price-to-earnings ratio of -6.47 and a beta of 1.31. Hinge Health has a 52-week low of $30.08 and a 52-week high of $91.50. The stock has a 50 day simple moving average of $74.52 and a 200 day simple moving average of $54.18.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Citigroup reissued an “outperform” rating on shares of Hinge Health in a report on Monday, July 27th. Zacks Research upgraded shares of Hinge Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Stifel Nicolaus lifted their price objective on Hinge Health from $79.00 to $90.00 and gave the company a “buy” rating in a report on Monday, July 27th. Evercore reiterated an “outperform” rating and set a $45.00 target price on shares of Hinge Health in a research report on Wednesday, April 8th. Finally, Weiss Ratings raised Hinge Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.07.

Insider Transactions at Hinge Health

In related news, Chairman Gabriel M.I. Mecklenburg sold 83,334 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $85.05, for a total transaction of $7,087,556.70. Following the completion of the sale, the chairman owned 83,334 shares of the company’s stock, valued at approximately $7,087,556.70. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Insight Holdings Group, Llc sold 181,499 shares of Hinge Health stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $90.20, for a total transaction of $16,371,209.80. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,921,100 shares of company stock worth $299,222,881. 18.92% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hinge Health

Several institutional investors and hedge funds have recently modified their holdings of HNGE. Wells Fargo & Company MN raised its holdings in shares of Hinge Health by 160.0% during the 4th quarter. Wells Fargo & Company MN now owns 546 shares of the company’s stock valued at $25,000 after buying an additional 336 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Hinge Health during the fourth quarter valued at approximately $26,000. CENTRAL TRUST Co acquired a new position in shares of Hinge Health during the first quarter worth $37,000. First Horizon Corp boosted its stake in shares of Hinge Health by 163.9% in the fourth quarter. First Horizon Corp now owns 855 shares of the company’s stock valued at $40,000 after purchasing an additional 531 shares during the period. Finally, High Point Wealth Management LLC acquired a new stake in Hinge Health during the 4th quarter valued at $46,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.